Abstract: The 7th Santorini Conference “Biologie Prospective,” held in collaboration with the European Society of Pharmacogenomics and Personalised Therapy (ESPT), focused on the transition from traditional, reactive medicine to the proactive era of Systems Medicine. Published in Drug Metabolism and Personalized Therapy (2014), this compendium of research highlights how the integration of "omics" technologies—genomics, proteomics, and metabolomics—with computational modeling is essential for realizing the promise of personalized health.
Introduction
The 7th Santorini Conference served as a pivotal gathering for researchers dedicated to the shift toward data-driven Systems Medicine. In this paradigm, the human body is no longer viewed as a collection of isolated organs but as a complex, integrated network. By combining multi-omics data with mathematical modeling, the field aims to uncover predictive pathways for drug response, overcome cancer resistance, and diagnose neurodegenerative diseases years before clinical symptoms manifest.
Addressing the Complexity of Chronic Disease
Traditional medicine often relies on a "one-size-fits-all" approach, which frequently fails to account for the inherent complexity and "missing heritability" of chronic conditions like Alzheimer’s, cancer, and diabetes. The conference addressed three central challenges:
- Inter-individual Variability: Understanding why patients with identical diagnoses respond differently to the same therapeutic interventions.
- Systemic Interactions: Mapping how environmental factors (the "exposome") interact with genetic predispositions over a lifespan.
- The Data Tsunami: Developing strategies to structure and analyze the massive volume of biological data currently being generated.
Methodological Innovations
The research presented utilized a diverse array of cutting-edge methodologies to bridge the gap between data and clinical utility:
- Human Metabolic Reconstruction: Utilizing community-effort databases to build mathematical models of human metabolism, enabling the prediction of biomarkers for rare diseases.
- In Silico Modeling: Developing dynamical models of gut-microbe interactions and cancer cell population evolution to simulate treatment outcomes.
- Pharmacogenomics (PGx): Using genotypic information, such as CYP2D6 or APOE variants, to guide precision dosing and mitigate adverse drug reactions.
- Ultra-sensitive Liquid Biopsies: Implementing DNA mass spectrometry (Ultraseek) to detect somatic mutations in peripheral circulation at abundances as low as 100 molecules per cc of plasma.
- Induced Pluripotent Stem Cells (iPSCs): Reprogramming patient-specific fibroblasts into dopamine neurons to create "disease-in-a-dish" models for Parkinson’s research.
Key Research Insights
Several transformative ideas emerged from the conference abstracts:
- Cilia as Signaling Hubs: Primary cilia were identified as ideal organelles for systems biology modeling due to their status as spatially and biologically distinct signaling hubs.
- The Role of Non-Coding DNA: Researchers are increasingly looking at structural variations (SVs) in non-coding regions (introns) to find the "missing heritability" that standard SNP analysis overlooks.
- Metabolism as a Driver: Shifts in metabolite levels are increasingly viewed as causes of pathogenic changes rather than mere symptoms, positioning metabolic reconstructions as fundamental diagnostic tools.
- The Exposome Concept: Health is redefined as the cumulative measure of environmental influences and associated biological responses throughout a lifespan, necessitating a move toward mechanistic environmental health studies.
Significant Results
- Alzheimer’s Diagnostics: A novel multiplex platelet protein biochip (measuring MaoB, Tm1, ApoE4, and GSTO1A140) achieved a ROC AUC of 0.969*, demonstrating exceptional accuracy in distinguishing Alzheimer’s patients from healthy controls.
- Breast Cancer Monitoring: A decrease in serum HER2 (S-HER2) of >20% correlated with a lack of disease progression in 20 out of 21 clinical courses (p < 0.0001), offering a robust tool for monitoring Herceptin therapy.
- Schizophrenia Biomarkers: A significant reduction in blood levels of xanthurenic acid was identified in schizophrenic patients and their first-degree relatives, suggesting a new marker for glutamatergic hypofunction.
- Regional Pharmacogenomics: A study of the Kosovar Albanian population successfully mapped 158 SNPs across 29 pharmacokinetic genes, establishing a vital baseline for personalized medicine in that region.
Limitations and Future Directions
Despite these advancements, the "implementation gap" remains a significant hurdle. Even when genetic markers are validated, educating prescribers and integrating this data into Electronic Medical Records (EMRs) is a complex task. Furthermore, while data generation has become inexpensive, the cost of adequately structuring that data remains high. Future efforts must focus on moving beyond single-nucleotide polymorphisms (SNPs) to understand how the gut microbiome and the exposome modulate genetic expression over time.
Summary updated